Author Archives: Terry McCormick

Decentralized R&D the “winning strategy”? – Apple begs to differ

There is a provocative piece in Aug 20 2012 issue (by Connie Guglielmo) of Forbes on Apple’s R&D, countering Pharma (and Tech) trend of decentralizing such efforts. Besides creating many high-level jobs and even more $B, is this creating a … Continue reading

Posted in General Interest, New R&D models | Leave a comment

 

Share

“The Truly Staggering Cost Of Inventing New Drugs”

Another provocative piece in Forbes  that implies the cost of developing a new drug could be as high as $12B!!  This approach has a number of flaws (as does: “Best Drug Companies.. “)  All produce (provoke?) some interesting insights from commenters.    Funny how … Continue reading

Posted in Uncategorized | Leave a comment

 

Share

“The Best Drug Companies Of The Past 15 Years?”

Matt Herper in Forbes’ “the Medicine Show” posts a point of view by Bernard Munos on what firms have done best in terms of approved drugs since 1995.  The link is here (http://onforb.es/zb6xgu), as are my comments on this provocative topic.  … Continue reading

Posted in Core Learnings, Financial, In the Pipeline | 1 Comment

 

Share

Innovation Upturn? New Medical Entities /$ Increasing!

A recent posting on Derek Lowe’s “In the Pipeline” presents a dismal view of the returns on R&D in Pharma.   BCG had included a graph (from Bernstein Research) of the trend of new molecular entities (“nme”) per $B spent over … Continue reading

Posted in Financial, Innovation, New R&D models | Tagged , | 4 Comments

 

Share

In-progress: NME’s .vs mergers

Note: The following focuses on New Medical Entities (NME’s.)  These are defined as the novel, initial member of a chemical family for a drug.  The data is derived from the public FDA database on approved drugs for past years.  From … Continue reading

Posted in Uncategorized | 2 Comments

 

Share

Another R&D model sea-change?

Reflections on GSK’s new R&D model collaborating with top “academic superstars” Continue reading

Posted in General Interest, New R&D models | 1 Comment

 

Share

Continued laments on R&D performance

Poor performance of Pharma R&D seems to have never left the newsservices or the hearts of all in the industry.  It is interesting to see the stories of 2011 echoing back for a decade.  Here are some current “news” items … Continue reading

Posted in Core Learnings, Financial, General Interest, Uncategorized | 1 Comment

 

Share

Outsourced R&D… a flawed Architecture?

Outsourced R&D – pro and con arguments (mostly con but interesting) Continue reading

Posted in Core Learnings | 1 Comment

 

Share

Corante’s “Big Pharma’s Lost Stock Market Decade”

Take a look at the posting and discussions on Derek Lowe’s excellent blog: http://pipeline.corante.com/archives/2010/12/13/big_pharmas_lost_stock_market_decade.php#comments     Another version of his chart is here, showing the last two years .vs. Lowe’s decade view.  It reveals the same result: the industry has underperformed the … Continue reading

Posted in Uncategorized | Leave a comment

 

Share

McKinsey article hits close to home…

While I have been using the name “R&D Returns” for years, I welcome this article from McKinsey.  Here, they call attention to the value of balanced R&D architecture and management.  Some of the sea-change tools cited on my home page here … Continue reading

Posted in Financial, General Interest, Research | Tagged , , | Leave a comment

 

Share